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Abstract 
Background: Hyperammonemia is known to cause neuronal injury, and can result from 
valproic acid exposure. Prompt reduction of elevated ammonia levels may prevent 
permanent neurological injury. We report a case of fatal hyperammonemic brain injury in a 
woman exposed to valproic acid.  
Case: A 38-year-old woman with schizoaffective disorder and recent increase in valproic acid 
dosage presented with somnolence and confusion and rapidly progressed to obtundation. 
Brain MRI showed diffuse bilateral restricted diffusion in nearly the entire cerebral cortex. 
She had normal liver function tests but serum ammonia level was severely elevated at 288 
μmol/l. Genetic testing showed no mutation in urea cycle enzymes. Despite successful 
elimination of ammonia with hemodialysis she developed fatal cerebral edema.  
Conclusion: Cerebral edema secondary to hyperammonemia is potentially reversible if 
recognized early. Ammonia excretion can be facilitated by initiation of hemodialysis and 
administration of scavenging agents (sodium phenylacetate and sodium benzoate). Severe 
hyperammonemia can result from valproic acid exposure even in the absence of 
hepatotoxicity or inborn errors of metabolism. It is important to check serum ammonia in 
any patient with encephalopathy who has had recent valproic acid exposure. 
 
Introduction 
Hyperammonemia is a well-described cause of encephalopathy and cerebral edema. 
When ammonia levels rise in the brain there is a subsequent swelling of astrocytes 
which results from the conversion of ammonia to glutamine. The resulting  
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inflammatory response and oxidative stress leads to cell loss through apoptosis [1]. 
Survival in cases of hyperammonemia requires management of intracerebral 
hypertension, supportive care and management of subclinical seizures (which appear 
in up to 40% of cases), and prompt reduction of ammonia levels either by reducing its 
production or facilitating its elimination. When hyperammonemia does not appear to 
be the direct result of liver failure, determining the cause can be challenging, but often 
points to a disorder in the urea cycle resulting in decreased ammonia elimination. Such 
disorders of ammonia metabolism may be inborn, although many medications, 
including valproic acid, can also disrupt the urea cycle. We report a case of fatal 
hyperammonemic encephalopathy and cerebral edema in a woman who was on 
valproate with normal liver function. 
Case Presentation 
We report the case of a 38-year-old Caucasian woman with schizoaffective disorder who presented 
to the hospital with one day of somnolence and confusion progressing to obtundation requiring 
intubation. She had been stable on perphenazine 4 mg qAM and 6 mg qPM and valproic acid until one 
week prior to presentation when her valproic acid was increased from 500 mg once a day to 500 mg 
twice a day in the setting of increased agitation and behavioral outbursts. She had also been in a low-
impact motor vehicle collision a month prior to presentation, and was taking cyclobenzaprine 10 mg 
tid for neck pain. Her only additional home medication was sertraline 100 mg qd. On presentation she 
was afebrile and tachycardic. She was rigid and clenching her jaw. She was not responsive to any 
stimuli. Her pupils were large and reactive and her eyes were intermittently deviated downward. She 
had slight withdrawal to painful stimuli in her upper extremities and posturing was noted in her 
lower extremities. She was hyperreflexic and had clonus in her ankles. She was given 
diphenhydramine and bromocriptine for initial concern for neuroleptic-malignant syndrome 
(serotonin syndrome was also considered). Laboratory work was notable for the following findings: 
urine toxicology screen positive for tricyclics and opiates, serum valproate level of 10.0 μg/ml, normal 
basic metabolic panel, normal liver function panel (AST/SGOT 15 U/l and ALT/SGPT 15 U/l), creatine 
kinase 295 U/l, thyroid stimulating hormone level of 2.3 U/ml, complete blood count with white blood 
cell count of 15,000 cells/ml. Her serum ammonia level was 288 μmol/l. Additional laboratory results 
are included in table 1. Further work-up included a chest X-ray demonstrating a right lower lobe 
consolidation (thought to be secondary to aspiration), a lumbar puncture without any evidence of 
infection or inflammation (opening pressure was not recorded, and there was no evidence of clinical 
or radiographic herniation after the lumbar puncture), a head CT with diffuse loss of the cortical gray-
white differentiation suggestive of cerebral edema, and an MRI of the brain with diffuse cortical 
restricted diffusion (fig. 1). An initial EEG showed diffuse slowing, but no seizure activity. 
We suspected that the patient was suffering from intracranial hypertension secondary to 
hyperammonemia-induced cerebral edema. In the setting of normal liver function studies an inborn 
disorder of urea cycle metabolism seemed likely, perhaps triggered by a recent increase in valproate 
dosing. To this effect, serum amino acid studies were notable for an elevated serum glutamine of 
1,292 μmol/l (consistent with the finding of hyperammonemia), and decreased levels of arginine (21 
μmol/l) and citrulline (9 μmol/l). No abnormal organic acids were detected. Table 1 provides a more 
complete listing of serum and urine amino acids levels. Serum orotic acid was elevated at 2.5 
mmol/mol-Cr. Genetic testing for ornithine transcarbamylase deficiency showed that no known OTC 
gene mutations were detected. 
The patient was started on a cooling protocol as well as hyperosmolar therapy with mannitol and 
23% sodium chloride solution for cerebral edema control. Hyperosmolar therapy administration and 
weaning follows a strict clinical protocol at our institution, where serum electrolytes and osmolality 
are monitored every 6 h or less, and serum sodium levels are kept within a very tight target range 
determined by the treating physicians. During weaning of hyperosmolar therapy, serum sodium is 
only allowed to decrease by 5 mEq/l every 24 h, and patients are monitored clinically and 
radiographically for rebound cerebral edema. Ammonia excretion was facilitated by initiation of 
continuous venovenous hemofiltration (CVVH), as well as by administration of lactulose and  
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scavenging agents (sodium phenylacetate and sodium benzoate) [2]. We attempted to decrease 
ammonia production by not allowing any protein intake and by administering arginine to help 
prevent protein catabolism (citrulline could not be obtained). After five days of CVVH her ammonia 
came down to 31 μmol/l and the dialysis was discontinued. She was found to be in nonconvulsive 
status epilepticus by EEG (with rhythmic activity starting in the occipital lobes; fig. 2) prompting the 
initiation of propofol and midazolam to induce burst suppression. Despite stopping depakote, her 
ammonia again began to rise up to 224 μmol/l, and CVVH was re-initiated without any further success 
in reducing the serum ammonia level. On hospital day 11 she became bradycardic with dilated, 
nonreactive pupils despite maximum osmotic therapy. Repeat imaging of her brain showed complete 
effacement of the supracellar cisterns suggesting further increase in her intracranial pressure and 
uncal herniation with global anoxic injury (fig. 3). At that time her goals of care were transitioned to 
focus on comfort measures only and she was terminally extubated. At autopsy her brain showed 
evidence of severe edema with flattening of gyri and both uncal and cerebellar herniation. Histology 
showed frequent Alzheimer type II cells throughout the cortex. Her liver was slightly pale and mildly 
enlarged. 
Conclusion 
Ammonia is produced in the gastrointestinal tract as a by-product of protein 
digestion; it is then metabolized primarily in the liver as urea. In cases of liver failure or 
urea cycle enzyme deficiencies, the metabolic capacity of the liver is overwhelmed and 
elimination of ammonia becomes dependent on other organs such as the kidneys and 
brain. The brain does not have a urea cycle; instead, astrocytes metabolize ammonia to 
glutamine via glutamine synthetase, resulting in intracellular hyperosmolarity and 
subsequent swelling and cell loss. This process results in triggering of inflammatory 
cascades, activation of NMDA-receptor pathways, and apoptosis, which in turn causes 
elevation in lactate, loss of cerebral autoregulation, and cerebral edema [1, 3]. 
Neuropathological studies in hyperammonemic syndromes reveal predominantly 
astrocytic swelling in the acute setting, and Alzheimer type II astrocytosis in the 
chronic setting [3]. Patients with hyperammonemia have elevated glutamine levels in 
serum, cerebrospinal fluid, and urine, and magnetic resonance spectroscopy can show 
high glutamine concentrations in the brains of patients with elevated ammonia 
regardless of the etiology. It is not clear why certain areas of the brain (i.e. the insular 
cortex, cingulate gyrus) seem particularly susceptible to the toxic effects of ammonia. It 
has been hypothesized that areas that are more metabolically active may be more 
affected by hypoperfusion and ischemia in the setting of elevated intracranial 
hypertension [4]. In the above case the MRI showed diffuse cortical involvement with 
some initial sparing of the primary motor and primary visual cortices (fig. 1); the 
significance of this pattern is unclear, but this has been demonstrated in previous case 
reports of hyperammonemic encephalopathy [5]. Previous case reports of 
hyperammonemic encephalopathy have also demonstrated the potential reversibility 
of cortical changes with aggressive treatment aimed at lowering the serum ammonia. In 
these cases, the extent of injury and reversibility also seemed to depend on the severity 
and duration of the hyperammonemia [3]. Reversible changes have not been described 
at levels of serum ammonia as high as that which our patient presented with. 
Valproate-induced hyperammonemic encephalopathy has been reported even in the 
absence of hepatotoxicity. It has been proposed that valproate may increase transport 
of glutamine across mitochondrial membranes making it more available for production 
of ammonia. It may also indirectly result in inhibition of the activity of carbamoyl-
phosphate synthase (CPS-1), a urea cycle enzyme, thereby decreasing ammonia  
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excretion [6]. In the above case our patient’s dose of valproate was recently doubled 
although her serum valproate level was not at a toxic level. This is consistent with 
previous case reports which have shown that the degree of hyperammonemia and 
encephalopathy is not necessarily related to the daily dose or serum valproate 
concentration [6]. It is worth noting that change in diet, stress of infection, exercise, and 
even hormones may influence ammonia levels. It remains unclear if the additional 
medications taken by our patient – sertraline, cyclobenzaprine, and perphenazine – 
played any significant role in her presentation. Furthermore, none of these medications 
have been described as potential causes of hyperammonemia in the setting of normal 
hepatic function. 
As described above, the presence of hyperammonemia in the setting of normal liver 
function studies raised a high level of suspicion for a possible inborn error of 
metabolism. In the urea cycle, ammonia is incorporated into an amino acid at each 
enzymatic step; accordingly, one ammonium ion is removed at each step until urea is 
formed. Hyperammonemia is most severe in these cases when the enzyme defect is an 
early step in the urea cycle, such as ornithine transcarbamylase (OTC) or carbamoyl-
phosphate synthase (CPS). OTC deficiency is one of the most common inborn errors of 
metabolism of the urea cycle, and as an X-linked disorder can have late onset 
presentations in women due to random X-inactivation due to mosaicism in each 
hepatocyte. Our hypothesis that our patient had an inborn error of metabolism was 
supported by her low serum citrulline and arginine levels; a defect in either OTC or CPS, 
two enzymes responsible for steps in the urea cycle which lead to the formation of 
these amino acids, could explain this deficiency. An elevated orotic acid level would be 
seen in OTC deficiency, but not in CPS deficiency, since orotic acid is a by-product of the 
cycle which is made from carbamoyl phosphate when OTC is not available. Over 200 
mutations have been identified in the ornithine carbamoyl transferase gene on 
chromosome Xp21, but genetic testing in this case did not show a recognized mutation. 
We cannot rule out the possibility that this patient may have had a novel mutation. In 
particular, a mutation in the promoter region of a gene, rather than the gene itself, may 
lead to similar deficiencies in key proteins of the urea cycle. 
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Table 1. Laboratory data 
                                              Value on 
admission 
Normal    Plasma amino 
acids 
Value on 
admission 
Normal    Urine amino 
acids 
Value on 
admission 
Normal 
                                            Na  143 mmol/l  136–145    Alanine  0.359  240–600    1-Methylhistidine  0.051  170–1,680 
K  3.7 mmol/l  .3.5–5.0    Arginine  00.21  040–160    Alanine  0.343  240–670 
BUN  8 mg/dl  0.6–23    Aspartic acid  000.9  000–20    Arginine  0.065  010–90 
Cr  0.74 mg/dl  00.5–1.2    Citrulline  000.9  010–60    Asparagine  0.108  099–470 
ALT/GPT  15 U/l  0.10–50    Cystine  00.26  007–70    Carnosine  0.038  010–90 
AST/GOT  15 U/l  .010–50    Glutamic acid  00.56  010–120    Citrulline  0.000  008–50 
CK  295 U/l  0.26–192    Glutamine  1,292  410–700    Cystine  0.016  043–210 
ALK PHOS  55 U/l  0.35–130    Glycine  0.158  140–490    Glutamic acid  0.005  039–330 
Tot Bili  0.4 mg/dl  00.0–1.0    Histidine  0.088  050–130    Glutamine  1,154  190–510 
Tot Prot  7.0 g/dl  06.4–8.3    Homocystine  000.0  000–0    Glycine  2,657  730–4,160 
Albumin  4.5 g/dl  03.5–5.2    Isoleucine  00.24  030–130    Histidine  0.392  460–1,430 
Glucose  137 mg/dl  0.54–118    Leucine  00.88  060–230    Isoleucine  000.5  016–180 
Ammonia  288 μmol/l  0.11–60    Lysine  0.137  080–250    Leucine  00.16  030–150 
WBC  15.57 K/μl  00.4–10    Methionine  00.17  017–53    Methionine  000.8  038–210 
HGB  14.5 g/dl  11.5–16.4    Omithine  00.41  020–135    Ornithine  000.3  020–80 
HCT  42.10%  0.36–48    Phenylalanine 00.64  030–80    Phenylalanine  00.19  051–250 
PLT  350 K/μl  .150–450    Proline  0.342  110–500    Proline  00.11  0.00 
ESR  5 mm/h  00.0–18    Serine  00.73  060–200    Serine  0.276  240–670 
PT (INR)  1.1 (N/A)  00.9–1.1    Taurine  00.38  025–80    Taurine  00.46  380–1,850 
PTT  27.2 s  23.8–36.6    Threonine  00.44  060–220    Threonine  00.32  130–370 
VALP ACID  10.0 μg/ml  0.50–120    Tyrosine  00.43  030–120    Tyrosine  00.35  090–290 
ACET LEVEL  <assay, μg/ml  0.10–20    Valine  0.143  140–350    Valine  00.16  027–260 
HAV IgM  Negative  n/a                 
HBsAg  Negative  n/a                 
HBsAb  Negative  n/a                 
HCV  Negative  n/a                 
TrepAb  Nonreactive  n/a                 
Mycoplasma  Neg lgG + IgM  n/a                 
Urine Organic  No unusual 
organic acids 
n/a                 
Methylmalonic 0.08 nmol/l  00.0–0.4                 
Serum Orotic  2.5 mmol/mol-
Cr 
00.4–1.2                 
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Fig. 1. MRI, hospital day 1. DWI on the left, ADC on the right. 
 
 
 
Fig. 2. EEG, hospital day 5. Rhythmic sharp theta discharges starting in the left occipital leads and 
evolving in amplitude, frequency and morphology, spreading to neighboring electrodes and to right 
occipital leads as well. 
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Fig. 3. CT, hospital day 1 on the left, hospital day 10 on the right. 
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